Navigation Links
Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
Date:1/12/2009

S. Food and Drug Administration (FDA). At that time, the FDA indicated that the data from the completed Phase 2 clinical studies of Amigal support the initiation of Phase 3 development and that Amigal was eligible for Accelerated Approval under Subpart H regulations. The FDA further indicated at that time that it was not opposed to the use of a surrogate primary endpoint, pending further discussions with the company.

Following this End of Phase 2 meeting, Amicus continued discussions with the FDA in the second half of 2008. The Agency has indicated that it supports a Phase 3 clinical trial comparing Amigal to placebo based on a surrogate primary endpoint of the change in the amount of kidney GL-3, the substrate that accumulates in the cells of Fabry patients. Amicus plans to continue discussions with the FDA through a Special Protocol Assessment (SPA) procedure that it commenced in the fourth quarter of 2008 to finalize how the primary endpoint will be measured. Amicus expects the SPA process to be complete in the second quarter of this year.

Based on discussions with the European Medicines Agency (EMEA), Amicus expects to initiate a separate clinical study designed to evaluate the safety and efficacy of Amigal versus ERT in Fabry patients. Amicus and its partner Shire HGT plan additional discussions with the EMEA in the first half of 2009 to finalize the design of this study.

In parallel with the Phase 3 regulatory discussions, 23 of the original 26 patients from the Phase 2 studies continue to be treated in a voluntary extension study to characterize the long-term safety and efficacy of Amigal and to evaluate additional doses and dose regimens. Data from this extension study are expected to be available in the first quarter of 2009 and the results will be used to finalize the dose and regimen for the Phase 3 studies.

Plicera(TM) (isofagomine tartrate) for the treatment of Gaucher Disea
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
2. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
3. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
4. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
5. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
6. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
7. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. Cara Therapeutics Initiates Phase II Proof-Of-Concept Trial of Novel Analgesic in Acute Post-Operative Pain
10. ExonHit Therapeutics Expands Strategic Collaboration With Allergan
11. Synvista Therapeutics Announces Published Data Demonstrating Elevation of Carboxymethyl-Lysine (CML) Is Associated with Decline in Renal Function and Arterial Stiffness in Older Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 1, 2014  SI-BONE, Inc., a medical device company that ... a minimally invasive surgical (MIS) device indicated for fusion for ... expansion of its European operations with the formation of a ... as General Manager, Germany.  Mr. Schaber will join former Kyphon ... Europe , Middle East ...
(Date:10/1/2014)... Oct. 1, 2014  CVS Health is thanking its ... role in changing the way health care is delivered ... the Company,s retail pharmacies, mail service pharmacies and specialty ... our company name to CVS Health to reflect our ... the innovations needed to shape the future of health," ...
(Date:10/1/2014)... Switzerland , October 1, 2014 ... Genomics and Next Generation Sequencing (NGS) data analysis, today ... run full cystic fibrosis analysis in a single NGS ... characterisation of all types of variants in a single ... Until now, it has not been possible to simultaneously ...
Breaking Medicine Technology:SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 2SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 3SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 4CVS Health Thanking its Pharmacists during American Pharmacists Month for Helping People on Their Path to Better Health 2CVS Health Thanking its Pharmacists during American Pharmacists Month for Helping People on Their Path to Better Health 3Sophia Genetics Launches Full CFTR Analysis in Single Clinical Grade NGS Experiment 2
... and JERUSALEM, Sept. 14, 2011 Chiasma, Inc., a privately ... CEO, will present an overview of the Company at the ... York, New York, on Monday, September 19, 2011 at 1:30 ... oral form of octreotide acetate being developed first for the ...
... Medical Technologies, Inc. and the Physician Services technology ... announced an agreement for INHS to provide Greenway,s ... solution PrimeSUITE® 2011 to hospital systems ... network interoperability. Established more than a ...
Cached Medicine Technology:Chiasma to Present at the UBS Global Life Sciences Conference 2Greenway Partners With INHS to Advance EHR Adoption 2Greenway Partners With INHS to Advance EHR Adoption 3
(Date:10/2/2014)... Dennis Thompson HealthDay Reporter ... of developing celiac disease isn,t reduced by breast-feeding. Nor will ... gluten to an infant,s diet help prevent celiac disease. ... studies in the Oct. 2 New England Journal of ... that a child could avoid celiac disease if mothers breast-feed ...
(Date:10/1/2014)... researchers from the University of Adelaide have developed a ... of a good outcome from treatment - from their ... on a range of factors, including clinical symptoms, cognitive ... in the patient,s blood. , Speaking in the lead ... University,s Head of Psychiatry , Professor Bernhard ...
(Date:10/1/2014)... research co-funded by the Engineering and Physical Sciences ... of the UK,s vital industrial control systems which ... electricity grid, and the rail network. , ... from hackers or malware infiltrating the systems behind ... Institute in Trustworthy Industrial Control Systems (RITICS), based ...
(Date:10/1/2014)... Marriagelifeinsurance.com has released a new blog ... couples. , Senior citizens can purchase a joint ... loved ones. A joint policy is cheaper, but will ... , Life insurance can be used to cover ... be purchased online, as the application process is simple ...
(Date:10/1/2014)... 01, 2014 Phoseon Technology, the pioneer ... to expand the business worldwide. This rapid growth includes ... capacity for manufacturing efforts. The company has experienced average ... years and expects this growth to continue in the ... gains worldwide adoption. , “We are very pleased ...
Breaking Medicine News(10 mins):Health News:Infant's Early Diet Doesn't Change Celiac Disease Risk, Study Finds 2Health News:Infant's Early Diet Doesn't Change Celiac Disease Risk, Study Finds 3Health News:Predicting the future course of psychotic illness 2Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:Elderly Life Insurance - Find Life Insurance for Retired Couples! 2Health News:Phoseon Technology Continues to Drive Growth Worldwide 2
... , , TAMPA, Fla. ... Solutions, today announced the appointment of Michael Unhjem as a member of ... (Logo: http://www.newscom.com/cgi-bin/prnh/20090709/FL43703LOGO ) , ... of Blue Cross Blue Shield (BCBS) of North Dakota, was unanimously elected ...
... SEATTLE, July 20 Group Health Cooperative medical centers received ... the Puget Sound Health Alliance Community Checkup . Group ... nine medical groups in the Puget Sound region that were rated on ... regional average" scores. , , "We support ...
... , MINNEAPOLIS, July 20 ... into a business relationship with Cardiocom(R) to provide advanced home ... Experts in Telehealth(SM), is a world class developer, manufacturer and ... , Cardiocom,s telehealth system provides an interactive ...
... 20 N y comed tod a y announced t h e su b mission of a N e ... n d Drug Administr a tion ( F DA) for ... oral treatme n t for patie n t s ... i ssion is ba s e d on enc ou raging result s fro m ...
... , , ... DIEGO, July 20 Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX ) today ... its investigational drug for the treatment of obesity, met their co-primary endpoints. ... O besity R esearch, or COR, program of more ...
... , , ... -- Allscripts (Nasdaq: MDRX ) announced today ... Human Resources. Ms. Adams brings to the position more than 20 ... high tech industry, most recently as Vice President of Human Resources ...
Cached Medicine News:Health News:Michael Unhjem Appointed to Board of Directors for Health Integrated 2Health News:Michael Unhjem Appointed to Board of Directors for Health Integrated 3Health News:Group Health Cooperative Scored Above Regional Average in 11 of 15 Quality Measures 2Health News:Silas Home Care Selects Cardiocom Telehealth Technology 2Health News:Nycomed Announces FDA Filing for Daxas(R) in COPD 2Health News:Nycomed Announces FDA Filing for Daxas(R) in COPD 3Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 2Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 3Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 4Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 5Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 6Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 7Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 8Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 9Health News:Diane Adams Joins Allscripts as Executive Vice President, Human Resources 2Health News:Diane Adams Joins Allscripts as Executive Vice President, Human Resources 3Health News:Diane Adams Joins Allscripts as Executive Vice President, Human Resources 4
One channel transcranial doppler with multigate, emboli detection, monitoring module and tests for hemodynamic evaluation. Looki 1TC is suitable as well for routine diagnosis as for monitoring in ope...
Locates flow easily, and identifies flow depth and direction for multiple vessels simultaneously....
Pakistani Watchmaker Forceps, 4" precision ground points....
Verte-Span is the latest advancement in vertebral body replacement technology. This device allows surgeons to reconstruct and stabilize certain types of anterior column defects in the spine....
Medicine Products: